Healthcare Services

Carcinoid Tumor Market Developments and Growth Opportunities Across 2026–2030

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Expansion Is Predicted For The Carcinoid Tumor Market Between 2026 And 2030?

The market size for carcinoid tumors has experienced significant expansion in recent years. It is anticipated to grow from $1.77 billion in 2025 to $1.96 billion in 2026, at a compound annual growth rate (CAGR) of 10.5%. This historical growth can be linked to improved awareness of rare cancers, the expansion of oncology care facilities, the availability of somatostatin analog therapies, the proliferation of cancer specialty clinics, and advancements in neuroendocrine tumor research.

The carcinoid tumor market is anticipated to experience substantial expansion in the coming years. This market is forecast to reach $2.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.1%. This projected growth during the forecast period is driven by factors such as the increasing creation of innovative targeted therapies, heightened investments in research for rare cancer treatments, the broadening of precision oncology methodologies, a greater uptake of personalized treatment regimens, and an intensified emphasis on patient quality-of-life outcomes. Key trends identified for this period encompass a rise in the adoption of targeted neuroendocrine tumor therapies, an increased application of combination drug regimens, a stronger focus on diagnosing tumors early, the proliferation of specialized oncology treatment centers, and a greater commitment to managing the disease over the long term.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21127&type=smp

What Drivers Are Influencing The Carcinoid Tumor Market?

The increasing obese population is anticipated to drive the expansion of the carcinoid tumor market. Obesity is defined as individuals having a body mass index (BMI) of 30 or higher, signifying excessive body fat. The growth in the obese population is attributed to factors such as unhealthy dietary habits, lack of physical exercise, sedentary lifestyles, and higher consumption of processed and high-calorie foods. Obesity contributes to the development of carcinoid tumors by promoting chronic inflammation, insulin resistance, and increased secretion of growth factors that aid tumor growth. For instance, in May 2025, data from the Office for Health Improvement and Disparities (OHID), a UK government agency, revealed that in 2023–2024, approximately 64.5% of adults (18+) in England were estimated to be either overweight or living with obesity, marking a slight rise from 64.0% in the preceding period (2022–2023). Consequently, the growing obese population is a significant driver for the growth of the carcinoid tumor market.

Which Market Segments Are Examined In The Carcinoid Tumor Market Study?

The carcinoid tumor market covered in this report is segmented –

1) By Disease Type: Gastrointestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Lung Neuroendocrine Tumor, Other Disease Types

2) By Treatment: Octreotide, Lanreotide, Telotristat ethyl, Capecitabine (Xeloda), 5-Fluorouracil (5-FU), Doxorubicin (Adriamycin), Etoposide (VP-16), Dacarbazine (DTIC), Streptozocin, Other Treatments

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By End User: Hospital And Clinics, Academic Institutions, Research Organizations

Subsegments:

1) By Gastrointestinal Neuroendocrine Tumor: Small Bowel Neuroendocrine Tumors, Colorectal Neuroendocrine Tumors, Appendiceal Neuroendocrine Tumors

2) By Pancreatic Neuroendocrine Tumor: Insulinoma, Non-insulinoma, Glucagonoma

3) By Lung Neuroendocrine Tumor: Typical Carcinoid Tumors, Atypical Carcinoid Tumors

4) By Other Disease Types: Thymic Neuroendocrine Tumors, Ovarian Neuroendocrine Tumors

What Trends Are Advancing Progress In The Carcinoid Tumor Market?

Major companies operating in the carcinoid tumor market are concentrating on advancements in diagnostic technologies, such as the fully automated chromogranin A test, to improve early detection and patient treatment outcomes. The automated chromogranin A (CgA) test refers to an entirely automated diagnostic tool used for measuring chromogranin A levels, a biomarker frequently linked with neuroendocrine tumors, including carcinoid tumors. As an illustration, in October 2023, Thermo Fisher Scientific Inc., a US-based biotechnology research company, received FDA clearance for its Thermo Scientific B·R·A·H·M·S CgA II KRYPTOR immunoassay. This achievement marks the first FDA-approved Chromogranin A (CgA) test and stands as the only automated immunoassay worldwide for monitoring tumor progression in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Designed to quantify CgA concentration in human serum, the assay empowers laboratories and cancer centers to track tumor development and assess treatment efficacy. By replacing manual laboratory-developed tests, it enhances lab operational efficiency and ensures more distinct result interpretation. The test functions on the Thermo Scientific B·R·A·H·M·S KRYPTOR compact PLUS random-access immunoassay analyzer, leveraging TRACE technology to deliver precise results within 30 minutes.

Who Are The Primary Competitors In The Carcinoid Tumor Market?

Major companies operating in the carcinoid tumor market are Novartis AG, Ipsen SA, Pfizer Inc, Merck & Co Inc, F Hoffmann-La Roche Ltd, Eli Lilly and Company, Sanofi SA, AstraZeneca PLC, Bristol Myers Squibb, Amgen Inc, Takeda Pharmaceutical Company, Bayer AG, Exelixis Inc, Lexicon Pharmaceuticals Inc, HUTCHMED, Crinetics Pharmaceuticals, Clovis Oncology, Taiho Pharmaceutical, Eisai Co Ltd, Teva Pharmaceutical Industries

Read the full carcinoid tumor market report here:

https://www.thebusinessresearchcompany.com/report/carcinoid-tumor-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Carcinoid Tumor Market?

North America was the largest region in the carcinoid tumor market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoid tumor market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Carcinoid Tumor Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21127&type=smp

Browse Through More Reports Similar to the Global Carcinoid Tumor Market 2026, By The Business Research Company

Cancer Immunotherapy Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report

Cancer Biomarker Global Market Report

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Chimeric Antigen Receptor T Car T Cells Global Market Report

https://www.thebusinessresearchcompany.com/report/chimeric-antigen-receptor-t-car-t-cells-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795